Open-Label Single-Arm Clinical Trial to Evaluate The Efficacy of Abatacept in Moderate to Severe Patch Type Alopecia Areata

Last Updated:
05/05/2016
Status:
Active/Fully Enrolled
Country:
United States
Eligibility:
Age 18-75; patch type alopecia areata
Drug:
Abatacept
Administration:
Injection
Sponsor: 
Columbia University

This study is ongoing but no longer recruiting participants.

Many people in the U.S. suffer from alopecia areata, yet treatment options are limited and sometimes painful. The goal of this study is to test a medication, given as a subcutaneous injection that acts on the immune system and may reverse hair loss. 

New York Presbyterian Hospital
Columbia University
New York, New York